TY - JOUR T1 - Safety and Effectiveness of COVID-19 SPUTNIK V Vaccine in Dialysis Patients JF - medRxiv DO - 10.1101/2021.10.21.21265349 SP - 2021.10.21.21265349 AU - Guillermo Rosa-Diez AU - María Marina Papaginovic Leiva AU - Fernando Lombi AU - María Soledad Crucelegui AU - Ricardo Dulio Martínez AU - Hernán Trimarchi AU - Rubén Schiavelli AU - Mercedes Grizzo AU - Miguel Raño AU - Ricardo M. Heguilén AU - Rocío Anahí Jones AU - Luciana Gonzalez Paganti AU - Matías Ferrrari AU - Dra. Paula Zingoni AU - Victoria Kjohede AU - Jorge Raúl Geffner AU - Daniel Ferrante AU - Fernán González Bernaldo de Quirós AU - Vanina Pagotto Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/25/2021.10.21.21265349.abstract N2 - Given the vulnerability of people with chronic kidney disease to COVID-19, nephrology societies have issued statements calling for prioritization of these patients for vaccination. It is not yet known whether COVID-19 vaccines confer the same high level of protection in patients with kidney disease. The aims of this study were to evaluate the safety measured by the events supposedly attributed to vaccines and the effectiveness evaluated by the presence of antibodies in dialysis patients immunized with the COVID-19 Sputnik V vaccine.Methods multicenter, observational and analytical study of a prospective cohort of hemodialysis patients in the Autonomous City of Buenos Aires with a vaccination plan. Patients older than 18 years on dialysis who received both components of the COVID-19 vaccine were included.Results 491 patients included in the safety analysis. ESAVI with either the first or second component was detected in 186 (37.9% 95% CI 33.6%-42.34%). The effectiveness analysis measures of antibodies against SARS-Cov-2 were performed in 102 patients, 98% had positive IgG against SARS-Cov-2 antibodies 21 days after the second component .In patients with COVID-19 prior to vaccination, antibodies at day 21 after the first component reached almost the highest levels compared to those patients who did not have COVID-19, and the rise between the last measures was lower than patients without COVID-19.Conclusion Dialysis patients constitute a vulnerable population for SARS-Cov-2 infection, beyond the recommendations that were implemented by dialysis units, full vaccination is a priority and necessary. The Sputnik V vaccine has been shown to be safe and effective in this patient population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe COVIDAR group provided the Serokits for sampling and the ELISA COVIDAR IgG kits, supported by FOCEM and Asoc. SAND. None of the funding sources provided economical support for the data collection, statistical analysis, or were used to write the manuscript, or to submit it for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Alberto C Taquini Institute for Translational Medicine Research of the Faculty of Medicine of the University of Buenos Aires.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -